MHRAsafety guidance65% confidence
Research: Use of UK plasma for the manufacture of five further plasma derived medicinal products and vCJD risk
Source: MHRA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Centaur Pharmaceuticals.
Regulatory Analysis
The Medicines and Healthcare products Regulatory Agency (MHRA) published a review of the safety of albumins manufactured from UK-sourced plasma with respect to variant Creutzfeldt-Jakob disease (vCJD) risk in August 2023.
Supporting Context
- Therapeutic area
- Diabetes · SGLT2 Inhibitor
- Sub-indication
- General
Related signal: Centaur Pharmaceuticals submits ANDA for Dapagliflozin